Jedrzej Borowczak
Overview
Explore the profile of Jedrzej Borowczak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
66
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Zdrenka M, Kowalewski A, Ahmadi N, Sadiqi R, Chmura L, Borowczak J, et al.
Biomol Biomed
. 2023 Oct;
24(1):14-29.
PMID: 37877810
Anti-programmed cell death ligand 1 (anti-PD-L1) immunotherapy is an increasingly crucial in cancer treatment. To date, the Federal Drug Administration (FDA) has approved four PD-L1 immunohistochemistry (IHC) staining protocols, commercially...
12.
Gostomczyk K, Marsool M, Tayyab H, Pandey A, Borowczak J, Macome F, et al.
Hum Cell
. 2023 Oct;
37(1):101-120.
PMID: 37874534
Circulating tumor cells (CTCs) are cancer cells that detach from the primary tumor, enter the bloodstream or body fluids, and spread to other body parts, leading to metastasis. Their presence...
13.
Zdrenka M, Kowalewski A, Borowczak J, Lysik-Miskurka J, Andrusewicz H, Nowikiewicz T, et al.
Clin Exp Med
. 2023 Oct;
23(8):5121-5127.
PMID: 37804360
PD-L1 expression is known to predict the benefits of immune checkpoint inhibitor therapy for triple-negative breast cancer (TNBC). We examined whether the PD-L1 expression evaluated in biopsy specimens accurately reflects...
14.
Kowalewski A, Jaworski D, Borowczak J, Maniewski M, Szczerbowski K, Antosik P, et al.
Int J Mol Sci
. 2022 Dec;
23(23).
PMID: 36499030
Resistance to systemic therapy is one of the hallmarks of renal cell carcinoma (RCC). Recently, TOLLIP has emerged as a possible driver of autophagy and chemoresistance. We explored the relationship...
15.
Borowczak J, Szczerbowski K, Maniewski M, Zdrenka M, Slupski P, Andrusewicz H, et al.
Clin Transl Oncol
. 2022 Nov;
25(3):830-840.
PMID: 36374405
Purpose: The mutation of p53 is considered a pivotal step in bladder cancer pathogenesis. Recently, distinct interactions between p53 and CDK9, a transcription regulator, have been described. In this work,...
16.
Solarz P, Bodnar M, Czech J, Mackiewicz-Nartowicz H, Sinkiewicz A, Szylberg L, et al.
J Med Virol
. 2022 Nov;
95(1):e28303.
PMID: 36369954
Recurrent respiratory papillomatosis is strictly connected with human papillomavirus (HPV) infection of the epithelium of the upper respiratory tract. The main treatment of lesions located in the larynx or lower...
17.
Borowczak J, Szczerbowski K, Maniewski M, Kowalewski A, Janiczek-Polewska M, Szylberg A, et al.
Biomedicines
. 2022 Jul;
10(7).
PMID: 35884974
The inflammatory process plays a significant role in the development of colon cancer (CRC). Intestinal cytokine networks are critical mediators of tissue homeostasis and inflammation but also impact carcinogenesis at...
18.
Borowczak J, Szczerbowski K, Maniewski M, Zdrenka M, Slupski P, Antosik P, et al.
Cancers (Basel)
. 2022 Mar;
14(6).
PMID: 35326643
Introduction: Most patients with urothelial carcinoma are diagnosed with non-invasive tumors, but the prognosis worsens with the progression of the disease. Overexpression of cyclin-dependent kinase 9 has been recently linked...
19.
Borowczak J, Szczerbowski K, Ahmadi N, Szylberg L
Med Oncol
. 2022 Jan;
39(4):39.
PMID: 35092513
Currently, multiple myeloma is not yet considered a curable disease. Despite the recent advances in therapy, the average patient lifespan is still unsatisfactory. Recently, CDK9 inhibitors emerged as a suitable...
20.
Kasperska A, Borowczak J, Szczerbowski K, Stec E, Ahmadi N, Szylber L
Curr Cancer Drug Targets
. 2021 Sep;
21(11):919-931.
PMID: 34525931
Desmoplasia is crucial for the development, progression and treatment of immune-resistant malignancies. Targeting desmoplasia-related metabolic pathways appears to be an interesting approach to expand our stock of disposable anti-tumor agents....